Accuray Appoints Experienced Commercial Leader Paul Miele as CCO to Drive Growth
ARAY sits 26% above its 52-week low of $0.33.
Summary
Accuray Inc. has appointed Paul Miele as its new Senior Vice President and Chief Commercial Officer, bringing extensive experience in driving sales growth and commercial transformation in medical technology.
Key Events · Executive and Board Changes · ARAY
-
New Chief Commercial Officer Appointed
Paul Miele has been named Senior Vice President and Chief Commercial Officer of Accuray, effective April 6, 2026.
-
Experienced Commercial Leader
Miele brings nearly two decades of global commercial leadership experience in medical technology, including a successful commercial turnaround at Johnson & Johnson MedTech's MONARCH robotic platform where he reversed revenue decline and generated double-digit sales growth.
-
Strategic Focus on Growth
He will lead Accuray's global commercial organization, focusing on sales, marketing, pricing, market access, and commercial partnerships to strengthen performance and drive value creation.
Analysis · ARAY · Industrial Applications And Services
This appointment is a significant strategic move for Accuray, especially following its recent restatement of Q1 2026 financials which revealed a substantial reduction in remaining performance obligations. Paul Miele's proven track record in rebuilding commercial operating models, accelerating sales, and reversing revenue declines at other medical technology companies directly addresses the company's need to strengthen its commercial performance and drive long-term value creation. Investors should monitor the impact of this new leadership on the company's sales execution and future financial results.
At the time of this filing, ARAY was trading at $0.42 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $49.3M. The 52-week trading range was $0.33 to $2.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.